openalexExperimental and Clinical Psychopharmacology2026-07-23
A 12-week study on the effects of betahistine (an H₃ antagonist/H₁ agonist) on cognitive functions in schizophrenia patients treated with olanzapine.
Hongyu Wang, Yongqian Wang, Weihao Huang, Wenshuang Yang, Qi Zhang, Wenxuan Zhao, et al.
Evidence on betahistine for cognitive impairment in schizophrenia is limited.This study evaluated its feasibility, safety, and preliminary efficacy to lay the groundwork for future randomized controlled trials.Thirty-one inpatients with schizophrenia, aged 18-60 years, undergoing…